Age [median (range) yr] |
7.9 (5.1–22.1) |
Sex, male [n (%)] |
19 (38) |
Race, Black [n (%)] |
5 (10) |
Tanner stage [n (%)] |
|
Prepubertal (Tanner 1) |
32 (64) |
Pubertal (Tanner 2–3) |
7 (14) |
Postpubertal (Tanner 4–5) |
11 (22) |
Age at leukemia diagnosis [median (range) yr] |
4.9 (1.4–19.7) |
Duration of therapy [median (range) yr] |
2.3 (1.3–3.4) |
Time since completion of therapy [median (range) yr] |
0.8 (0.0–2.2) |
Diagnosis [n (%)] |
|
Precursor B ALL |
49 (98) |
T-cell ALL |
1 (2) |
Leukemia risk [n (%)] |
|
Standard |
33 (66) |
High |
17 (34) |
Cumulative Steroids [n (%), median (range)] |
|
Dexamethasone (g/m2) |
49 (98), 1.1 (0.1–1.6) |
Prednisone (g/m2) |
15 (30), 4.3 (0.5–6.8) |
Nonphalangeal fractures (n) |
(10 fractures; 9 patients) |
At leukemia diagnosis |
2 |
During leukemia treatment |
7 |
After leukemia treatment |
1 |
Laboratory parameters [median (range)] |
|
Calcium (mg/dl) |
9.4 (8.9–10.2) |
Intact PTH (pg/ml) |
29 (3–66) |
25(OH)D (ng/ml) |
30.9 (4.1–93.6) |